Abstract: Therapeutic pharmaceutical compositions comprising a pyrimidine derivative in combination with camptothecin or a camptothecin derivative for the treatment of cancer are described. In one embodiment, the pyrimidine derivative is capecitabine and the camptothecin derivative is CPT-11.
Abstract: T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2′-deoxyguanosine and/or prodrugs thereof; and certain PNP inhibitors.
Type:
Grant
Filed:
December 17, 2001
Date of Patent:
December 9, 2003
Assignee:
BioCryst Pharmaceuticals Inc.
Inventors:
Shanta Bantia, John A. Montgomery, Philip E. Morris, Jr.
Abstract: The present invention relates to the use of selenium and/or a derivative thereof in combination with one or more cytostatics.
It is the object of the present invention to provide a possibility of enhancing the effect of antitumor drugs, and to provide said drugs in a suitable form of administration.
Said object is achieved by using selenium and/or at least one selenium compound for enhancing the effect of one or more cytostatics. This combination results in a synergistic, i.e. superadditive, enhancement of the effect. Furthermore, the present invention provides a kit containing selenium and/or at least one selenium compound and one or more cytostatics as a combination preparation for cytostatic therapy. The present invention can be used efficiently against various types of tumor cells, but especially against large-cell and small-cell bronchial carcinomas, adenocarcinomas, pancreatic carcinomas, prostatic carcinomas and hypemephromas.
Abstract: The invention refers to pharmaceutical compositions suitable for the protection of the mitochondrial genome and/or mitochondrium from damages for the treatment of diseases connected with such damages, said compositions comprising a hydroximic acid derivative of formula I or a pharmaceutically acceptable acid addition salt therefor.
Abstract: Methods for treating cancer are provided that involve administration of a combination of the chemotherapeutic drug, temozolamide, and thymidine.
Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.
Type:
Grant
Filed:
August 9, 2001
Date of Patent:
October 21, 2003
Assignee:
Novartis AG
Inventors:
Terence O'Reilly, Markus Wartmann, Manuel Litchman, Pamela Cohen
Abstract: Methods of administering camptothecin compounds such as irinotecan hydrochloride to reduce a diarrhea side effect and methods of treating cancer and AIDs with camptothecin compounds including administering the camptothecin compounds while maintaining the intestinal lumen and the bile at an alkaline pH.
Abstract: The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of Formula I as defined herein in combination with paclitaxel, taxotere or modified taxane or taxoid analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.
Abstract: Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen a substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.
Type:
Grant
Filed:
October 2, 2001
Date of Patent:
October 14, 2003
Assignee:
Orion Corporation
Inventors:
Kaija Af Ursin, Jukka Salmia, Heikki Niskanen, Pirjo Kortesuo, Mikko Kananen, Gunilla Örn, Juha Kiesvaara
Abstract: A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.
Abstract: The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I:
wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group; and
wherein said compound is substantially in the form of the (−) enantiomer.
Abstract: Novel phenyl-substituted 1,4-dihydropyridines, prepared by reacting halogenophenyl-aldehydes with &bgr;-ketoesters, if appropriate with isolation of the ylidene compounds and enamines. The substances can be employed as active compounds in medicaments, in particular in cerebrally active compositions.
Type:
Grant
Filed:
February 12, 2001
Date of Patent:
October 7, 2003
Assignee:
Bayer Aktiengesellschaft
Inventors:
Heinrich Meier, Wolfgang Hartwig, Bodo Junge, Rudolf Schohe-Loop, Zhan Gao, Bernard Schmidt, Maarten de Jonge, Teunis Schuurman
Abstract: Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhibit the activity of other such kinases (e.g. CDC2 and CDK2). This specificity results in an improved therapeutic index when used as drugs to treat susceptible cancers.
Type:
Grant
Filed:
February 18, 2000
Date of Patent:
October 7, 2003
Assignee:
The United States of America as represented by the Department
of Health and Human Services
Inventors:
Michael J. Kelley, Kazuhiko Nakagawa, Barry Roy Dent
Abstract: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a naphthalimide and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the naphthalimide comprises amonafide (5-amino-2-[2-(dimethylamine)ethyl]-1H-benz[de-]isoquinoline-1,3-(2H)-dione). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes. The invention comprises the described methods as well as compositions comprising a naphthalimide and an antiproliferative agent.
Abstract: A method of treating specific forms of cancer with water-insoluble 20(S)-camptothecin compounds with the closed-lactone ring intact and/or derivatives thereof is disclosed. The method includes administering the compounds intramuscularly, orally and transdermally.
Type:
Grant
Filed:
January 18, 2002
Date of Patent:
September 23, 2003
Assignee:
The Stehlin Foundation For Cancer Research
Inventors:
Beppino C. Giovanella, Hellmuth R. Hinz, Anthony J. Kozielski, John S. Stehlin
Abstract: A method for enhancing the effect of anti-tumor agents on solid tumors is provided. The method comprises administering to an individual an anti-tumor agent and a hematocrit elevator. The hematocrit elevator may be administered before or concurrently with the anti-tumor agent.
Abstract: Medicinal compositions for colorectal cancer to be administered to the large intestine by taking advantage of preparations disintegrating in the large intestine, characterized by containing a cyclooxygenase inhibitor and an HMG-CoA reductase inhibitor. These compositions are appropriate for inhibiting the postoperative liver metastasis and recurrence of colorectal cancer.
Abstract: The present invention provides a method for preventing or treating osteoporosis in a castrated prostatic cancer patient, by administering to the patient an amount of from 10 mg to 300 mg cyproterone acetate per day. The present therapy is compatible with the patients' anti-cancer treatment.
Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
Abstract: Alkanoyl L-carnitines of the formula:
where R is hydrogen or a C2-8 alkanoyl group and X− is an anion of a pharmaceutically acceptable salt, are used in conjunction with anticancer agents such as taxol or bleomycin to improve the therapeutic index and reduce side effects typical of anticancer chemotherapy.